Novel and emerging pharmacologic treatments for Schizophrenia

Schizophrenia has been treated for more than 70 years with dopamine receptor antagonists or partial agonists, whose efficacy is thought to be related to a reduction of postsynaptic dopamine transmission. These so-called first- and second-generation ”antipsychotics” have been foundational for the management of schizophrenia and psychosis in general, but treatment gaps remain.

In this video Professor Christoph Correll discusses the challenges we have with the available schizophrenia treatments today. He also touches upon what clinicians should keep in mind when considering the emerging treatment options for their patients living with schizophrenia.

Christoph U Correll, MD

Professor and Chair of the Department of Child and Adolescent Psychiatry, Charité University Medicine, Berlin, Germany and also Professor of Psychiatry at The Zucker School of Medicine at Hofstra/Northwell, New York, USA.